Acadia pulls plug on pimavanserin for adjunctive MDD
US regulators have, however, accepted the drug for review to treat hallucinations and delusions associated with dementia-related psychosis
Read More
Tag: pimavanserin
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
